A Phase 4 interventional study of Icotinib and chemotherapy (Carboplatin and Docetaxel) in Neoplasms, Therapy-Associated, sponsored by Chinese PLA General Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-11-05.
Sponsored by Chinese PLA General Hospital · Phase 4, Interventional, and Treatment
This is a randomized ,opened, prospective controlled trial of clinical effectiveness for Icotinib as the adjunctive treatment after surgery in stage I-IIIB lung adenocarcinoma patients with epidermal growth factor receptor gene mutation
In this trial the investigators will enlist 100 patients who accepted surgery and with epidermal growth factor receptor gene mutation,these patients will be divided into 2 groups (chemotherapy group and Icotinib group),compare the PFS,RFS,OS after 5 years follow up
2,004 studies on the registry are indexed under Adenocarcinoma; 375 are open to participants now.
This study's planned enrollment of 10 is below the median of 45 across 1,553 interventional studies indexed under Adenocarcinoma.
Browse Adenocarcinoma studies →Chinese PLA General Hospital is the lead sponsor of 558 studies on the registry; 202 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Carboplatin,350mg/m2,1/3weeks Docetaxel,75mg/m2,1/3weeks
Drug: Icotinib · Drug: chemotherapy (Carboplatin and Docetaxel)
Icotinib, 125mg,3/D,2years
Drug: Icotinib · Drug: chemotherapy (Carboplatin and Docetaxel)
compared with chemotherapy,which is better for lung adenocarcinoma patients with epidermal growth factor receptor gene mutation after surgery
Also known as: Conmana
as control group,compared with Icotinib
Also known as: Carboplatin and Docetaxel
Recurrence-free Survival
Time frame: 6 months
Overall survival
Time frame: 6 months
This study is status unknown, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chinese PLA General Hospital